MISFEASANCE AND NON-FEASANCE IN THE LIABILITY OF PUBLIC AUTHORITIES. II

被引：0

|

作者：

Moore, W. Harrison

机构：

来源：

LAW QUARTERLY REVIEW | 1914年 / 30卷 / 120期

关键词：

D O I：

暂无

中图分类号：

D9 [法律]; DF [法律];

学科分类号：

0301 ;

摘要：

引用

收藏

页码：415 / 432

页数：18

相关论文

共 49 条

[41] Medicine, Government and Public Health in Philip II's Spain: Shared Interests, Competing Authorities
Dominguez, Frank A.
SIXTEENTH CENTURY JOURNAL, 2013, 44 (01): : 319 - 320
[42] Medicine, Government, and Public Health in Philip II's Spain: Shared Interests, Competing Authorities
Poska, Allyson M.
EUROPEAN HISTORY QUARTERLY, 2014, 44 (01) : 137 - 138
[43] Medicine, Government and Public Health in Philip II's Spain: Shared Interests, Competing Authorities
Walker, Timothy D.
BULLETIN OF THE HISTORY OF MEDICINE, 2012, 86 (04) : 681 - 683
[44] Medicine, Government and Public Health in Philip II's Spain. Shaed Interests, Competing Authorities
Pardo-Tomas, Jose
HISPANIA-REVISTA ESPANOLA DE HISTORIA, 2014, 74 (248): : 857 - 861
[45] TOWARDS A NEW GOVERNANCE: PUBLIC AUTHORITIES AND THIRD SECTOR. A NECESSARY BUT NON-EXISTENT RELATIONSHIP
Gomez Calvo, Veronica
Romero Tarin, Adela
BARATARIA-REVISTA CASTELLANO-MANCHEGA DE CIENCIAS SOCIALES, 2016, (21) : 163 - 173
[46] The Non-Contractual Nature of Civil liability for Damages Caused in the Provision of the Public Health Service in Colombia
Giraldo Gomez, Luis Felipe
REVISTA ESTUDIOS SOCIO-JURIDICOS, 2022, 24 (01): : 267 - 298
[47] Type II ROS1 inhibitors and their liability on ROS1 rearranged non-small cell lung cancer with L2086F mutation
Thawani, Rajat
Keddy, Clare
Repetto, Matteo
Jones, Kristen
Nicholson, Katelyn
Beach, Zoe
Drilon, Alexander
Davare, Monika
MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
[48] NEGLIGENCE - PUBLIC AUTHORITIES - COSTS - PLAINTIFF SUCCEEDED AGAINST COUNCIL AND TRUST BUT FAILED AGAINST STATE AND GRANDPARENTS - TRIAL JUDGE DECLINED TO MAKE BULLOCK OR SANDERSON ORDER - WHETHER ERROR IN FAILING TO FIND THAT COUNCIL CAUSED PLAINTIFF TO JOIN OTHER PARTIES - NON-ACCEPTANCE OF CALDERBANK LETTER - WHETHER TRIAL JUDGE ERRED IN MAKING PARTIAL INDEMNITY COSTS ORDER
Prince, Thomas
AUSTRALIAN LAW JOURNAL, 2021, 95 (03): : 181 - 185
[49] Simulation of phase III studies of motesanib 125 mg once daily (QD) plus carboplatin/paclitaxel (CPM) or bevacizumab plus carboplatin/paclitaxel (CPB) versus carboplatin/paclitaxel (CP) in first-line non-small cell lung cancer (NSCLC) using a public domain drug-disease modeling framework and phase II data.
Ciaret, L.
Lu, J.
Bruno, R.
Sikorski, R. S.
Hei, Y.
Sun, Y.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

← 1 2 3 4 5 →